Neonatal Biotinidase

Neonatal Biotinidase Specification

Technology
Modern

Portable
Yes

Use
Medical Use

Function
Hospital Use

Color
Multicolor

Condition
New

Application
For Hospital amd Clinic Purpose

Neonatal Biotinidase Trade Information

Minimum Order Quantity
1 Piece

Payment Terms
Cash in Advance (CID), Cheque, Cash Advance (CA)

Supply Ability
1 Piece Per Week

Delivery Time
1-6 Week

Main Domestic Market
All India

About Neonatal Biotinidase

overview

The fluorescent reaction product formed as a result of the biotinidase activity is measured. This is based on direct enzyme assay in which the dietary protein or biotin intake does not influence.

Technical Specifications

Neonatal Biotinidase, 5 solid plates (96), 480 wells 6199 820
Neonatal Biotinidase, 10 solid plates (96), 960 wells 6199 821

Benefits

Easy to perform
No centrifuging or filtration step needed
Fluorescence detection provides high sensitivity
Assay is compatible with Labsystems Diagnostics NS2400 automation system

Advanced Technology for Enhanced Screening

Our Neonatal Biotinidase device incorporates the latest advancements in medical diagnostics, making it a reliable tool for early detection of newborn metabolic disorders. Designed for both hospitals and clinics, it features intuitive controls and an efficient process, ensuring timely and accurate results for newborn screening programs.

Designed for Portability and Clinical Use

This device is engineered for versatility and ease of use, providing lightweight, portable operation without compromising precision. The multicolor options support clear identification and workflow organization, making it suitable for busy hospital environments and outreach clinics. Its modern build ensures longevity and effortless maintenance.

FAQs of Neonatal Biotinidase:

Q: How does the Neonatal Biotinidase device function in a hospital or clinic setting?

A: The device functions by screening newborns for biotinidase deficiency through a straightforward and fast testing process. Samples are processed with high accuracy, enabling clinical teams to quickly identify metabolic disorders and initiate timely treatment.

Q: What are the primary benefits of using this modern Neonatal Biotinidase device?

A: The main benefits include early detection of biotinidase deficiency, improved patient outcomes through prompt intervention, portability for flexible use across different clinical settings, and reliable results due to advanced technology.

Q: When should hospitals or clinics use the Neonatal Biotinidase device?

A: It should be used as part of routine newborn screening programs, immediately after birth, to ensure that potential metabolic issues are identified and addressed at the earliest possible stage.

Q: Where can this device be implemented within healthcare facilities?

A: The Neonatal Biotinidase device is suitable for neonatal units, pediatric departments, mobile screening units, and clinics, providing comprehensive screening coverage wherever newborns are assessed.

Q: What is the process for using the Neonatal Biotinidase device?

A: The process involves collecting a small blood sample from the newborn, placing it in the device, and following the automated instructions. The device quickly analyzes the sample and provides clear, actionable results for the healthcare team.

Q: How does the device prove beneficial for hospital workflows?

A: Its portability and multicolor system streamline organization, while the rapid processing reduces waiting time, supporting efficient decision-making and smoother patient management in busy hospital environments.